Crab-shaped DNA tetrahedral nanomachine for silencing undruggable mRNA targets in prostate cancer
Source abstract
Abstract
Cancer-associated gene fusions and mutations have emerged as a promising wellspring of therapeutic neoantigens. However, the lack of a precise and expeditious drug design pipeline has unfortunately missed the opportunity for timely treatment. Due to the intricate and arbitrary nature of these mutations and fusions, navigating the intricate terrain of 3D protein structures presents additional challenges. Despite significant advancements in targeted therapy, there are still a significant number of targets that cannot be effectively targeted, hindering further therapeutic efficacy. Moreover, the conditional efficacy of RNA interference through siRNA is compromised by the off-target phenomena, leading to associated toxic side effects. To address these limitations, we have developed a meticulously engineered DNA nanostructure in the form of a captivating crab-shaped DNA tetrahedron. This design not only ensures efficient interference with mRNA, but also facilitates ease and rapidity in synthesis. Additionally, it demonstrates an unprecedented ability to suppress the expression of previously considered "undruggable", which are crucial in targeted therapies. Through in vivo experimentation within a murine prostate cancer model, the DNA nanostructure has shown significant effectiveness in overcoming drug resistance, thus clearly displaying its substantial potential for clinical translation applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Protein Degradation and Inhibitors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Siegel · CA Cancer J. Clin. · 2022 · 72 · 7
2. Xia · Chin. Med J. · 2022 · 135 · 58410.1097/CM9.0000000000002108 ↗
3. Sandhu · Lancet · 2021 · 398 · 107510.1016/S0140-6736(21)00950-8 ↗
4. Tran · Science · 2009 · 324 · 78710.1126/science.1168175 ↗
5. Auchus · Annu Rev. Med. · 2020 · 71 · 3310.1146/annurev-med-051418-060357 ↗
6. Tosco · Eur. Urol. · 2019 · 75 · 4410.1016/j.eururo.2018.07.027 ↗
7. Heinlein · Endocr. Rev. · 2004 · 25 · 27610.1210/er.2002-0032 ↗
8. Antonarakis · N. Engl. J. Med. · 2014 · 371 · 102810.1056/NEJMoa1315815 ↗
9. Hu · Cancer Res. · 2009 · 69 · 1610.1158/0008-5472.CAN-08-2764 ↗
10. Toren · Mol. Cancer Ther. · 2015 · 14 · 5910.1158/1535-7163.MCT-14-0521 ↗
11. Liu · Oncogene · 2014 · 33 · 314010.1038/onc.2013.284 ↗
12. Jamaspishvili · Nat. Rev. Urol. · 2018 · 15 · 22210.1038/nrurol.2018.9 ↗
13. Teng · Protein Cell · 2021 · 12 · 2910.1007/s13238-020-00786-8 ↗
14. Zhang · Expert Opin. Drug Discov. · 2022 · 17 · 5510.1080/17460441.2021.1969359 ↗
15. Henley · Nat. Rev. Drug Discov. · 2021 · 20 · 66910.1038/s41573-021-00199-0 ↗
16. Seeman · J. Theor. Biol. · 1982 · 99 · 23710.1016/0022-5193(82)90002-9 ↗
17. Ranallo · Anal. Chem. · 2019 · 91 · 4410.1021/acs.analchem.8b05009 ↗
18. Xie · Nanoscale · 2018 · 10 · 545710.1039/C7NR09692E ↗
19. Zhang · Nat. Protoc. · 2020 · 15 · 272810.1038/s41596-020-0355-z ↗
20. Madhanagopal · Trends Biochem Sci. · 2018 · 43 · 99710.1016/j.tibs.2018.09.010 ↗
21. Goodman · Science · 2005 · 310 · 166110.1126/science.1120367 ↗
22. Liang · Angew. Chem. Int. Ed. Engl. · 2014 · 53 · 774510.1002/anie.201403236 ↗
23. Walsh · ACS Nano · 2011 · 5 · 542710.1021/nn2005574 ↗
24. Xia · Mater. Interfaces · 2018 · 10 · 1544210.1021/acsami.8b02626 ↗
25. Pei · Acc. Chem. Res. · 2014 · 47 · 55010.1021/ar400195t ↗
26. Vargason · Nat. Biomed. Eng. · 2021 · 5 · 95110.1038/s41551-021-00698-w ↗
27. Petros · Nat. Rev. Drug Discov. · 2010 · 9 · 61510.1038/nrd2591 ↗
28. Rupaimoole · Nat. Rev. Drug Discov. · 2017 · 16 · 20310.1038/nrd.2016.246 ↗
29. Lu · Nat. Rev. Cardiol. · 2019 · 16 · 66110.1038/s41569-019-0218-x ↗
30. D. Adams, A. Gonzalez-Duarte, W.D. O'Riordan, C.C. Yang, M. Ueda, A.V. Kristen, I. Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.P. Lin, G. Vita, S. Attarian, V. Plante-Bordeneuve, M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan, 3rd, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, O.B. Suhr, N. Engl J. Med., 379 (2018), pp. 11–21.10.1056/NEJMoa1716153 ↗
31. H.-A. Collaborators
32. Poli · Mol. Genet Metab. · 2022 · 135 · 20610.1016/j.ymgme.2022.01.002 ↗
33. O.-. Investigators10.1056/NEJMoa1913805 ↗
34. Sas · Genet Med. · 2022 · 24 · 65410.1016/j.gim.2021.10.024 ↗
35. Kulkarni · Acc. Chem. Res. · 2019 · 52 · 243510.1021/acs.accounts.9b00368 ↗
36. Revia · Acc. Chem. Res. · 2019 · 52 · 149610.1021/acs.accounts.9b00101 ↗
37. Lee · Nat. Nanotechnol. · 2012 · 7 · 38910.1038/nnano.2012.73 ↗
38. Zhang · Nano Lett. · 2018 · 18 · 565210.1021/acs.nanolett.8b02166 ↗
39. He · ACS Nano · 2017 · 11 · 406010.1021/acsnano.7b00725 ↗
40. Han · Nano Today · 2021 · 3810.1016/j.nantod.2021.101203 ↗
41. Eskra · Prostate Cancer Prostatic Dis. · 2021 · 24 · 22010.1038/s41391-020-00272-6 ↗
42. Sahu · EMBO J. · 2011 · 30 · 396210.1038/emboj.2011.328 ↗
43. Joseph · Cancer Discov. · 2013 · 3 · 102010.1158/2159-8290.CD-13-0226 ↗
44. Zhu · Clin. Transl. Med. · 2022 · 12
45. Raap · Virchows Arch. Int. J. Pathol. · 2017 · 471 · 50110.1007/s00428-017-2142-y ↗
46. Fedchenko · Diagn. Pathol. · 2014 · 910.1186/s13000-014-0221-9 ↗
47. Qian · Chem. Rev. · 2023 · 123 · 778210.1021/acs.chemrev.2c00915 ↗
48. Xie · Signal Transduct. Target Ther. · 2023 · 8
49. Li · Cancer Res. · 2011 · 71 · 210810.1158/0008-5472.CAN-10-1998 ↗
50. Li · Med Res. Rev. · 2019 · 39 · 148510.1002/med.21558 ↗
51. Elshan · Med Res. Rev. · 2019 · 39 · 91010.1002/med.21548 ↗
52. Li · Nature · 2020 · 580 · 9310.1038/s41586-020-2135-x ↗
53. Gao · Nat. Genet. · 2020 · 52 · 101110.1038/s41588-020-0681-7 ↗
54. Chan · Clin. Exp. Pharmacol. Physiol. · 2006 · 33 · 53310.1111/j.1440-1681.2006.04403.x ↗
55. Yang · Mol. Diagn. Ther. · 2020 · 24 · 110.1007/s40291-019-00443-9 ↗